Pediatrics

Q109. Discuss Post-Infectious (Post-Streptococcal) Glomerulonephritis (PSGN): pathogenesis, clinical presentation, complement dynamics, biopsy indications, and management.

Pathogenesis

PSGN results from immune complex-mediated glomerular injury following infection with nephritogenic strains of Group A Streptococcus — classically following pharyngitis (latent period 1–2 weeks) or skin infection/impetigo (latent period 3–6 weeks).

Deposition of streptococcal antigen-antibody immune complexes within the glomerular basement membrane triggers complement activation and glomerular inflammatory injury — a proliferative glomerulonephritis with characteristic "hump-shaped" subepithelial immune deposits on electron microscopy where biopsy is performed.

Clinical Presentation

The classic acute nephritic triad: hematuria (often grossly visible, "cola" or "tea-colored" urine), edema (typically periorbital, prominent on waking), and hypertension (from sodium/water retention). Oliguria may be present, and, in more severe cases, features of AKI.

Complement (C3) Dynamics – Key Diagnostic/Monitoring Tool

Serum C3 is typically markedly reduced during the acute phase, with characteristic normalization within approximately 6–8 weeks.

Kidney Biopsy Indications

Biopsy is NOT routinely required for typical presentations with a clear preceding streptococcal infection history and expected complement dynamics. Reserved for atypical presentations:

• Absence of a clear preceding streptococcal infection history
• Failure of C3 to normalize within the expected 6–8 week window
• Significant, persistent, or worsening renal impairment beyond typical PSGN
• Nephrotic-range proteinuria (atypical for straightforward PSGN)
• Clinical features suggesting an alternative or additional diagnosis

Acute Management

Predominantly supportive: salt and fluid restriction, diuretic therapy for edema/hypertension, antihypertensives for significant hypertension, and renal function monitoring.

Q110. Discuss Chronic Kidney Disease (CKD) in children: staging, management of anemia, growth failure, and CKD-Mineral Bone Disorder.

CKD Staging in Children

Follows the same fundamental eGFR-based framework used in adults (Stages 1–5, Stage 5/eGFR <15 mL/min/1.73m² = ESRD requiring RRT or transplantation), using pediatric-specific eGFR estimation formulas (e.g., the Schwartz formula, incorporating height and serum creatinine).

Management of Anemia (Erythropoiesis-Stimulating Agents)

CKD-associated anemia results predominantly from reduced renal erythropoietin production, managed with Erythropoiesis-Stimulating Agents (ESAs) combined with adequate iron supplementation (oral, or IV where oral is inadequate) — iron deficiency is common in CKD and will otherwise blunt ESA effectiveness.

Management of Growth Failure

A particularly significant, characteristic complication of pediatric CKD, reflecting a multifactorial combination of: chronic metabolic acidosis, inadequate caloric intake (anorexia/uremia), CKD-associated mineral bone disease, and relative growth hormone resistance (normal/elevated GH levels but impaired end-organ responsiveness/IGF-1 generation).

Management includes optimizing nutrition, correcting metabolic acidosis, managing mineral bone disease, and, for persistent growth failure despite these measures, recombinant growth hormone therapy.

CKD-Mineral Bone Disorder (CKD-MBD)

As GFR declines, phosphate retention occurs, driving both direct suppression of active vitamin D synthesis (inhibiting renal 1α-hydroxylase) and secondary hyperparathyroidism (from resulting hypocalcemia and phosphate's direct stimulatory effect on PTH secretion), producing renal osteodystrophy.

Management: dietary phosphate restriction, phosphate binders (with meals), and active vitamin D (calcitriol) or analogs — maintaining calcium, phosphate, and PTH within stage-appropriate target ranges.

Preparation for Renal Transplantation

Proactive preparation for eventual RRT, ideally with pre-emptive transplantation (before dialysis is required) as the preferred approach where feasible, given superior outcomes compared to a period of dialysis preceding transplantation.

Q111. Discuss Urinary Tract Infection (UTI) and Vesicoureteral Reflux (VUR) in children: AAP imaging guidelines, VUR grading, and the antibiotic prophylaxis controversy.

AAP Guidelines for First Febrile UTI in Infants (2–24 months)

Reflects a more conservative, selective imaging approach than older, historical practice:

• Renal and bladder ultrasound — recommended for essentially all infants following a first febrile UTI, screening for major structural abnormalities without radiation exposure
• Voiding Cystourethrogram (MCU/VCUG) — NOT recommended routinely after a first febrile UTI in the absence of specific risk factors

MCU is specifically recommended when: ultrasound reveals hydronephrosis, scarring, or findings suggestive of high-grade VUR/obstructive uropathy; recurrent febrile UTI occurs; or other atypical features are present (atypical organism, poor treatment response, suggestive family history).

VUR Grading (International Reflux Study Group)

Higher-grade VUR (particularly IV–V) is associated with substantially greater risk of renal scarring, recurrent febrile UTI, and, long-term, hypertension and CKD.

Antibiotic Prophylaxis Controversy

A genuinely, actively debated area:

• For prophylaxis (particularly higher-grade VUR III–V): the landmark RIVUR trial demonstrated a statistically significant reduction in recurrent febrile/symptomatic UTI — but notably without a corresponding significant reduction in new renal scarring on follow-up imaging
• Against routine prophylaxis: concern regarding antimicrobial resistance, and RIVUR's finding of increased risk of resistant-organism infection among children on prophylaxis when breakthrough UTI occurred

Q112. Discuss Dysnatremic Dehydration: hyponatremic and hypernatremic dehydration, pathophysiology, and safe correction principles.

Hyponatremic Dehydration

Occurs when water losses are accompanied by proportionally greater sodium losses, or when free water replacement has been disproportionately generous relative to sodium replacement (e.g., replacing diarrheal losses predominantly with plain water or an inappropriately dilute fluid). Hypotonic extracellular fluid drives water into cells, including brain cells, causing cellular swelling — a particular concern in the brain given the skull's fixed volume constraint, risking cerebral edema (headache, altered mental status, seizures, brainstem herniation).

Hypernatremic Dehydration

Occurs when water losses substantially exceed sodium losses (classically prolonged diarrhea with inadequate free water replacement, or inappropriately concentrated formula). Hypertonic extracellular fluid draws water out of cells; the brain generates intracellular osmolytes ("idiogenic osmoles") to protect against excessive cellular shrinkage. This adaptation becomes dangerous during correction: if hypernatremia is corrected too rapidly, water rushes INTO brain cells (which still contain accumulated osmoles), causing cerebral edema — the mirror-image risk to overly rapid hyponatremia correction.

Overarching Conceptual Summary

Both directions share the same underlying principle: the brain's compensatory cellular osmotic adaptations to chronic dysnatremia become a liability during correction if it proceeds faster than the brain's compensatory mechanisms can re-adapt — hyponatremia correction risks demyelination (relative brain cell dehydration), while hypernatremia correction risks cerebral edema (relative brain cell over-hydration).

Q113. Discuss Antenatal Hydronephrosis (ANH) and Posterior Urethral Valves (PUV): UTD classification, pathophysiology, and management.

Evaluation of Antenatal Hydronephrosis – UTD Classification

The Urinary Tract Dilation (UTD) classification system is the current, standardized, multidisciplinary consensus framework for grading antenatally (and postnatally) detected urinary tract dilation — incorporating anteroposterior renal pelvic diameter, calyceal dilation, renal parenchymal thickness/appearance, ureteral dilation, and bladder abnormality, combined into risk categories (UTD A1, low risk; UTD A2-3, increasing risk) that guide postnatal follow-up intensity.

Pathophysiology of Posterior Urethral Valves (PUV)

PUV is the most common cause of significant lower urinary tract obstruction in male infants (male-only, given the specific embryological posterior urethral anatomy), from abnormal obstructing membranous folds within the posterior urethra — causing bladder outlet obstruction with retrograde back-pressure effects: bladder wall hypertrophy/trabeculation, bilateral hydroureteronephrosis, and renal parenchymal damage/dysplasia during the critical period of nephron development.

Early Catheterization

Prompt bladder catheterization (feeding tube or small urethral catheter) provides immediate, temporary bladder decompression as soon as PUV is confirmed/strongly suspected — halting ongoing back-pressure injury while diagnostic confirmation (typically VCUG, demonstrating a dilated, elongated posterior urethra with a visible obstructing valve leaflet, often with associated VUR) and surgical planning proceed.

Definitive Fulguration

Endoscopic fulguration (ablation) via cystoscopy once stable is the definitive treatment (sometimes preceded by temporary vesicostomy in very small/premature infants until sufficient size is reached).

Q114. Discuss Peritoneal Dialysis in Infants: indications, acute vs chronic PD, catheter/dialysate considerations, and PD peritonitis.

Indications

Peritoneal dialysis is used for both acute and chronic kidney failure requiring RRT, and is particularly favored in infants/young children given several advantages over hemodialysis: avoids specialized vascular access (technically challenging in small infants), superior hemodynamic tolerability (gradual, continuous removal vs abrupt shifts with intermittent hemodialysis), and simpler equipment/infrastructure requirements.

Acute vs Chronic PD

Catheter Insertion

Requires careful technique to minimize immediate complications (bleeding, bowel/bladder injury given confined abdominal space in small infants) and longer-term complications (malposition/malfunction, exit-site/tunnel infection).

Dialysate Composition

Contains glucose (dextrose) as the primary osmotic agent for ultrafiltration, at various concentrations for titration, plus electrolytes (calcium, magnesium, sodium) and a buffer (traditionally lactate, increasingly bicarbonate-based for better biocompatibility). Icodextrin-based solutions (glucose polymer, colloid osmotic mechanism) are increasingly used for the longest overnight dwell in automated PD, given superior sustained ultrafiltration.

Prevention and Management of PD Peritonitis

The major, most feared complication — abdominal pain, cloudy dialysate effluent, and fever. Diagnosis confirmed via dialysate effluent cell count and Gram stain/culture (elevated WBC with neutrophil predominance).

Prevention centers on rigorous, structured training of the child/family in aseptic exchange technique (touch contamination is the most common source), proper catheter exit-site care, and prompt treatment of exit-site/tunnel infection before progression to established peritonitis.

Q115. Discuss IgA Nephropathy and Henoch-Schönlein Purpura (HSP) Nephritis: shared pathogenesis, clinical spectrum, MEST-C classification, and treatment.

Pathogenesis – Galactose-Deficient IgA1

Both IgA Nephropathy (primary, isolated renal disease) and HSP Nephritis (renal involvement as part of the broader HSP/IgA vasculitis syndrome, additionally involving palpable purpuric rash, arthralgia/arthritis, and abdominal pain) share a common molecular pathogenic mechanism, increasingly understood as points along a single disease spectrum.

Both are characterized by abnormal galactose-deficient IgA1 molecules, recognized as "foreign," triggering anti-glycan autoantibodies. The resulting IgA1-containing immune complexes deposit within the glomerular mesangium, triggering complement activation and mesangial proliferation/inflammatory injury — explaining both conditions' characteristic mesangial IgA deposition on immunofluorescence.

Clinical Spectrum

IgA Nephropathy: classically episodic macroscopic hematuria, often coinciding with or shortly following an upper respiratory tract infection (the classic "synpharyngitic" hematuria pattern — distinguishing it from PSGN's distinct 1–2 week latent period), interspersed with microscopic hematuria, and, in a subset, progressive proteinuria and declining renal function.

HSP Nephritis: occurs within the broader HSP syndrome (palpable purpura, typically lower extremities/buttocks; arthralgia/arthritis; abdominal pain with intussusception risk) — renal involvement ranges from asymptomatic microscopic hematuria/mild proteinuria through to nephritic or, less commonly, nephrotic-range proteinuria, with a minority progressing to renal impairment.

Oxford MEST-C Classification

A standardized, semi-quantitative histopathological classification used for both conditions, scoring biopsy findings across:

• M — Mesangial hypercellularity
• E — Endocapillary hypercellularity
• S — Segmental glomerulosclerosis
• T — Tubular atrophy/interstitial fibrosis
• C — Crescents (later revision, particularly relevant to acute pediatric presentations)

This provides standardized, reproducible prognostic information correlating with long-term renal outcome and increasingly informs treatment decisions.

Immunosuppressive Therapy

Mild disease (isolated hematuria, minimal proteinuria) is managed conservatively with ACE inhibitor/ARB therapy for proteinuria reduction/renoprotection. More significant disease (nephrotic-range proteinuria, significant biopsy findings including crescents, or declining renal function) warrants immunosuppressive therapy, typically corticosteroids, with cyclophosphamide, mycophenolate mofetil, or other steroid-sparing agents for more severe or refractory presentations, particularly with significant crescentic change.

Q116. Discuss Bartter and Gitelman Syndromes: shared features, distinguishing biochemistry, and long-term treatment.

Shared Features – Inherited Tubular Channelopathies

Both are inherited (typically autosomal recessive) disorders of renal tubular electrolyte transport, both producing hypokalemia and metabolic alkalosis — impaired sodium chloride reabsorption at the affected tubular segment triggers compensatory RAAS activation, and the resulting secondary hyperaldosteronism drives increased distal potassium and hydrogen ion secretion.

Comparison Table

Long-Term Treatment

Electrolyte replacement — potassium supplementation (often substantial doses), and, particularly for Gitelman, magnesium supplementation. Potassium-sparing diuretics (spironolactone, amiloride, eplerenone) help counteract secondary hyperaldosteronism-driven potassium wasting. NSAIDs (indomethacin) are additionally used, particularly in more severe Bartter syndrome, given prostaglandin-mediated contribution to clinical severity.

Q117. Discuss Autosomal Recessive vs Autosomal Dominant Polycystic Kidney Disease (ARPKD vs ADPKD): genetics, presentation, extrarenal manifestations, and prognosis.

Genetics

ARPKD results from mutations in PKHD1; both parents (typically asymptomatic carriers) must contribute a mutant allele. ADPKD results from PKD1 or PKD2 mutations; an affected parent may themselves be entirely asymptomatic/undiagnosed at the time a child is evaluated, making family history exploration (including parental imaging) important.

Age of Presentation and Clinical Course

ARPKD classically presents early — often prenatally or in the neonatal period — sometimes with sufficiently severe involvement to cause oligohydramnios and consequent pulmonary hypoplasia. ADPKD is classically adult-onset (hypertension, hematuria, flank pain, progressive decline), though renal cysts can be present and detectable on careful imaging even in childhood in individuals who will go on to develop the classic adult syndrome.

Extrarenal Manifestations

ARPKD is characteristically associated with congenital hepatic fibrosis (periportal fibrosis, abnormal bile duct development) with risk of portal hypertension. ADPKD extrarenal manifestations include hepatic cysts (without the fibrotic/portal hypertension complications of ARPKD), intracranial (berry) aneurysms (elevated subarachnoid hemorrhage risk, particularly with a family history of aneurysm rupture), and cardiac valvular abnormalities (mitral valve prolapse).

Clinical Course

ARPKD carries variable but generally more immediately severe prognosis with significant early mortality in the most severely affected, though survivors of the neonatal period can have a substantially more prolonged course. ADPKD follows a gradually progressive course over decades, with most individuals not reaching ESRD until mid-to-late adulthood.

Q118. Discuss Central vs Nephrogenic Diabetes Insipidus: etiology, the water deprivation/desmopressin challenge test, and management.

Etiology

Central (Neurogenic) DI results from inadequate ADH (vasopressin) secretion from the posterior pituitary — causes include CNS tumors/lesions (craniopharyngioma being a particularly classic pediatric cause given its suprasellar location), traumatic brain injury, CNS infection, and idiopathic/autoimmune causes (a substantial proportion of pediatric central DI, sometimes as part of Langerhans Cell Histiocytosis).

Nephrogenic DI results from renal tubular resistance/insensitivity to ADH despite normal or elevated circulating levels — congenital forms (X-linked V2 receptor mutations, or autosomal aquaporin-2 gene mutations) and acquired forms (lithium, chronic hypercalcemia, chronic hypokalemia, obstructive uropathy).

Water Deprivation Test Protocol

The central diagnostic tool for evaluating suspected DI and distinguishing it from primary polydipsia. Involves supervised fluid restriction with serial monitoring of urine osmolality, serum osmolality, and body weight (careful monitoring given dehydration risk). In normal individuals/primary polydipsia, urine osmolality rises appropriately as endogenous ADH is triggered; in true DI (either type), urine osmolality fails to concentrate despite the physiological stimulus.

Vasopressin/Desmopressin Challenge – Distinguishing Central from Nephrogenic

Management

Central DI: desmopressin (DDAVP) replacement (oral, intranasal, or parenteral), directly replacing the deficient hormone — with careful monitoring for water intoxication/hyponatremia from excessive dosing.

Nephrogenic DI: cannot be treated with desmopressin (fundamental renal unresponsiveness). Management focuses on: adequate free water intake matching obligate losses, a low-sodium, low-protein diet (reducing osmotic solute load), and, paradoxically, thiazide diuretics (induce mild volume depletion, secondarily increasing proximal reabsorption, reducing distal delivery and urine output), sometimes combined with NSAIDs (reduce renal prostaglandin's ADH-antagonizing effect at the collecting duct).